AUPH vs. OCUL, PRAX, PRTC, PLRX, LBPH, BCYC, ARCT, ZNTL, EOLS, and PAHC
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Ocular Therapeutix (OCUL), Praxis Precision Medicines (PRAX), PureTech Health (PRTC), Pliant Therapeutics (PLRX), Longboard Pharmaceuticals (LBPH), Bicycle Therapeutics (BCYC), Arcturus Therapeutics (ARCT), Zentalis Pharmaceuticals (ZNTL), Evolus (EOLS), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical preparations" industry.
Ocular Therapeutix (NASDAQ:OCUL) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
Aurinia Pharmaceuticals received 143 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 73.07% of users gave Aurinia Pharmaceuticals an outperform vote while only 69.74% of users gave Ocular Therapeutix an outperform vote.
59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 5.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Aurinia Pharmaceuticals has a net margin of -32.69% compared to Aurinia Pharmaceuticals' net margin of -138.15%. Ocular Therapeutix's return on equity of -15.06% beat Aurinia Pharmaceuticals' return on equity.
Aurinia Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.
In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Aurinia Pharmaceuticals and 12 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.47 beat Aurinia Pharmaceuticals' score of 0.07 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
Ocular Therapeutix currently has a consensus price target of $17.60, suggesting a potential upside of 196.80%. Aurinia Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 95.31%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Ocular Therapeutix is more favorable than Aurinia Pharmaceuticals.
Summary
Aurinia Pharmaceuticals beats Ocular Therapeutix on 10 of the 18 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
